Please login to the form below

Not currently logged in
Email:
Password:

J&J appoints quality-control chief

Johnson & Johnson has created a new position at the company to oversee all quality, manufacturing and compliance issues 

In the wake of a series of major recalls of its nonprescription medicines, Johnson & Johnson (J&J) has created a new position at the company to oversee all quality, manufacturing and compliance issues.

Ajit Shetty, who is chairman of the board and managing director of the J&J subsidiary Janssen Pharmaceutica, has been tapped to fill the new post. He will serve as a corporate vice president of J&J, reporting directly to company CEO William Weldon, and will oversee quality improvement efforts for J&J's pharmaceutical, consumer products, medical device and diagnostics groups.

Shetty has been with J&J since 1976. He was raised in India but holds an MBA from Carnegie Mellon University in the US, as well as a PhD from Trinity College/Cambridge University in the UK.

In addition, J&J said it has appointed chief quality officers for each of its three major business units. Those positions will report to Shetty.

The recalls, which caused a PR crisis for J&J, involved Children's Tylenol, Motrin and St Joseph aspirin, the allergy drug Benadryl, the antacid Rolaids and Simply Sleep pills.

The products were manufactured at a Pennsylvania factory that has been temporarily shuttered, as well as at another facility in Puerto Rico. Some products were contaminated with bacteria, while others were made with the wrong amount of active ingredient, and still others contained metal shavings.

19th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics